Applying breakthrough science to develop life-saving vaccines for people in need around the globe
A next-generation, broad-coverage pneumococcal disease vaccine
Despite a number of commercially available vaccines,
Streptococcus pneumoniae infections are still responsible for more than 1,000,000 deaths worldwide per year!
We are developing a next-generation, recombinant protein vaccine to profoundly reduce the devastating global impact of pneumococcal disease.
Streptococcus pneumoniae
Clostridiodes difficile
A novel C. difficile vaccine that targets the bacteria and the toxins
Clostridiodes difficile, classified by the US Centers for Disease Control and Prevention (CDC) as an urgent public health threat, is estimated to cause half a million infections per annum in the US alone.
We are developing a novel, triple antigen C. difficile vaccine that targets the bacteria and the toxins, reducing bacterial colonization and preventing toxicity.